Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma

NCT00982592 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00982592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00982592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
October 31, 2014
Enrollment
124 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the gastroesophageal junction, adenocarcinoma of the stomach, recurrent gastric cancer, stage iiia gastric cancer, stage iiib gastric cancer, stage iiic gastric cancer, stage iv gastric cancer